摘要
目的：评价白蛋白结合型紫杉醇治疗老年晚期非小细胞肺癌的近期疗效和安全性。方法：回顾性分析老年患者48例，年龄在70岁以上。白蛋白结合型紫杉醇130mg／m0，dl、8，3周重复，至少2周期后评价疗效。结果：病人中位年龄74岁，总有效率（RR）51％，TTP183d，中位生存时间411d，1年生存率52％。最常见的不良反应为骨髓抑制，Ill～Ⅳ级中性粒细胞减少占8．3％，恶心／呕吐占4．2％，脱发占6．5％。结论：白蛋白结合型紫杉醇治疗老年晚期非小细胞肺癌疗效较好，不良反应轻，安全性好。是治疗老年晚期非小细胞肺癌的理想药物。
Objective： This study aimed to investigate the clinical efficacy and adverse effects of nab - pacli- taxel in elderly patients with advanced non- small cell lung cancer. Methods： A retrospective analysis of 48 cases of elserly patients ages over 70 years old. All patientsWere treated with 130 mg/m2 nab - paclitaxel on days 1, 8, The cycle was repeated every 3 weeks. Clinical efficacy was evaluated every two cycles. Results： Patients with a median age 74 years, RR was 51%, and TTP was183 days. The median time to progression was 411 days, one year survival rate was 52 %. The major adverse reactions included neutropenia （8.3%）, and nausea and vomit- ing（4.2 % ）, alopecia （6. S % ）. Conclusion：Nab- paclitaxel has curative effects, and its adverse effects are tol- erable.
出处
《内蒙古医学杂志》
2013年第8期922-924,共3页
Inner Mongolia Medical Journal
关键词
老年
非小细胞肺癌
白蛋白结合型紫杉醇
安全性
Old age
Non - small cell lung cancer
Albumin - bound qaclitacel
Security
